2016 PRECLINICAL DRUG DISCOVERY RFP

The Alzheimer’s Drug Discovery Foundation (ADDF) seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer’s disease, other dementias and cognitive aging.

FUNDING MECHANISMS

- **Academic Program** seeks to create and support innovative translational programs in academic medical centers and universities.

- **Biotechnology Program** helps to create new biotechnology companies, and to fund existing biotechnology companies, with programs dedicated to Alzheimer’s disease drug discovery. Funding is provided through program-related investments (PRIs) that require return on investment based upon scientific and/or business milestones.

2016 PRECLINICAL RESEARCH FUNDING PRIORITIES

- **Drug Discovery** - Target validation and lead optimization, high throughput screening, medicinal chemistry - including hit to lead development and lead optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharmacokinetics and pharmacodynamics, and in vivo proof-of-concept with lead compounds and biologics.

- **Biomarker Development** - Development of blood, CSF, and imaging biomarkers to accelerate clinical trials, allow for accurate and early diagnosis, and to track disease progression.

With regards to potential drug targets:

- The ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s disease, related dementias and cognitive aging. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers.

- The ADDF has limited interest in funding anti-amyloid approaches, including anti-amyloid aggregation programs, Abeta vaccine development and beta or gamma-secretase inhibition programs. The ADDF also has limited interest in funding cholinesterase inhibitor programs.

Programs areas of particular interest include:

- **Repurposing** – Testing drugs approved for other indications in Alzheimer’s disease preclinical models. Proposals should be hypothesis driven and drugs chosen for testing should target a mechanism of action(s) common to both diseases.

- **New chemical compounds for Alzheimer’s disease** – Requires BOTH a medicinal chemist and a biologist as co-PIs/collaborators. The program should focus on new scaffolds, generation of tool compounds, improving CNS-focused chemical libraries, and optimizing novel lead compounds.

- **Preclinical proof-of-concept** – Testing of novel lead compounds in animal models. Study design should be clearly outlined along the lines of an exploratory or therapeutic animal study as described in the ADDF’s recent publication, *Accelerating Drug Discovery for Alzheimer’s Disease: Best Practices for*
Preclinical Animal Studies. Whenever possible, studies should include pharmacokinetics (PK) and pharmacodynamics (PD) testing, an *a priori* hypothesis and primary and secondary outcomes measures, and a statistical design plan including power analysis.

APPLICATION SUBMISSION GUIDELINES
The ADDF provides typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $150,000-$600,000 per year depending on the stage of research and must be justified based on the scientific work plan. In some cases, multi-year proposals can be considered. Inquiries with the ADDF staff are encouraged to determine the Foundation’s interest prior to application. All applicants are required to complete an electronic "Letter of Intent" (LOI) available through our website. LOIs are due at least 2 weeks before the application deadline and are reviewed on a rolling basis. After review of the LOI, ADDF may invite a full application via email with a link to the electronic application form. The ADDF will attempt to make a determination of interest within 90 days of receipt of the application. Full application guidelines and further information can be found on our website (http://www.alzdiscovery.org).

ADDF ACCESS
Applicants are encouraged to sign up for the ADDF ACCESS portal to gain access to an online marketplace of contract research organizations (CROs) and a virtual network of experts and educational resources. For guidance on selecting and managing CROs, please see ADDF’s recent publication.

2016 QUARTERLY DEADLINES*
March 18
June 3
September 2
December 9

*Letter of Intent is due at least two weeks prior to deadline

For program related inquiries: Lauren Friedman, PhD
 Assistant Director, Scientific Affairs
 Phone: 212-901-8017
 lfriedman@alzdiscovery.org

For application submission inquiries: Dan Teng
 Grants Assistant
 Phone: 212-901-7998
 dteng@alzdiscovery.org